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Sir, 
We are delighted at the publication of Holford and Buclin's article1, which proposes a general theoretical 
framework for the clinical problem of individualizing drug doses. The essence of their proposal is that a 
careful assessment of between-patient and within-patient variability in the pharmacokinetic or 
pharmacodynamic response of interest should be made to decide whether a target concentration 
intervention (TCI) is appropriate, and should be made prior to formulating a TCI. Although Holford and 
Buclin do not give details about how these variabilities should be computationally combined with a 
particular patient’s drug plasma concentrations and covariate values in order to implement a TCI in 
practice, their description of criteria to determine whether or not a TCI is necessary is an important 
contribution. Another reason for our enthusiasm is that Holford and Buclin’s framework is conceptually 
equivalent to a rigorous mathematical formulation of dose individualization that we developed in 
several prior publications.2,3,4 In fact, we can say that if a pharmacologist is willing to computationally 
implement Holford and Buclin’s ideas in a TCI by using standard statistical software, or to rigorously 
derive further practical and methodological consequences of these ideas for therapeutic drug 
monitoring (TDM), then he/she may want to read our publications as a next step.2,3,4   
Each and every pharmacokinetic concept described in Holford and Buclin's article has a corresponding 
and equivalently defined concept in our mathematical formulation. Table 1 describes the equivalence 
between Holford and Buclin’s concepts and some of our concepts. We hope that this table serves as a 
guideline for those who want to proceed to read our more mathematically demanding papers.2,3 A 
friendly introduction for clinicians and pharmacologists, and epistemological consequences of the 
approach are in reference 4. Our mathematical formulation of dose individualization is based on random 
effects linear models, a family of statistical models that is well known and widely used by professional 
statisticians, but that, unfortunately, is not well known by pharmacologists.  We celebrate that Holford 
and Buclin seem to have been inspired by random-effects ideas. This is suggested by the fact that they 
cite a work from the Sheiner School in their paper,5 a school that for decades have advocated the use of 
random-effects models (also called mixed regression models) for developing dose individualization 
methods. The Sheiner School, however, places emphasis on random-effects nonlinear models, not linear 
models, which is a reason to consider Holford and Buclin’s ideas a significant conceptual jump.  
The fact that other authors have independently developed ideas about dose individualization that are 
essentially equivalent to ours confirms that random effects linear models are the natural mathematical 
language of a pharmacological theory and practice of dose individualization.4 Our mathematical 
formulation based on these models provides answers to important questions that are not addressed in 
Holford and Buclin’s article. For instance, 1) How can we compute an optimal dose for a particular 
patient, that is, what is the optimal way of combining steady-state concentrations from an individual 
patient with his/her demographic, clinical or genetic covariates in order to obtain an appropriate dose 
for the patient?; 2) What is the minimum number of blood samples at steady state that are needed from 
a patient in order to compute an optimal dose for that patient?; and 3) Do dose individualization 
methods currently used in TDM produce optimal doses?.  After laying out  the term “optimal dose” with 
a concept that we have called omega-optimality, we have demonstrated through both decision-
theoretical arguments and computer simulations that a traditional TDM method of dose 
individualization that is advocated in many pharmacology textbooks does not produce optimal doses 
(see also footnote h to Table 1).3 Also, we have computed a table that provides the minimum number of 
blood samples that are needed from individual patients in order to obtain an omega-optimum dose for a 
high percentage of the patients in the population.2 Finally, the basic tenet of the Sheiner School, that an 
empirical Bayesian approach should be used to amalgamate all the available information from a patient 
with prior population information in order to search for an optimum  dose  for the patient, can be 
shown to be particularly valid (and easy to implement computationally) when random effects linear 
models are used.2,3  
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Table 1. List of concepts that Holford and Buclin1 use to build their approach to dose individualization, and the conceptually equivalent concepts 
that Diaz et al.2,3 use to build their statistical model and clinical algorithm for target concentration intervention.      
Holford and Buclin’s1  concept     Symbol useda Diaz et al.’s2,3 equivalent conceptb    Symbol(s) usedc 
Target concentration    TC  Target concentrationd      𝐶0  
Safe and effective concentration range  SECR  Target concentration range (TCR)    (𝑙1, 𝑙2) 
Unpredictable between-subject variability BSVU  Between-subjects variancee     𝜎𝛼
2 
Unpredictable within-subject variability  WSVU  Intra-individual random error     𝜎𝜖
2 
Unpredictable variability   PPVU  Total variance of log of steady-state plasma concentrations 𝜎𝛼
2 + 𝜎𝜖
2 
Predictable variability    PPVP  Combination of fixed effects and covariatesf   𝜇𝛼 + 𝜷
𝑇𝑿  
Safe and effective variability   SEV  Fraction of maximum attainable probability    𝜔 × 𝑚, 𝜔 ≈ 1 
that patient reaches TCRg  
Individual target dose    ITD  Dose computed at second step of individualization algorithmh 𝐷2 
Clearance     CL  Patient’s concentration-to-dose ratio at steady statei  𝑒𝛼+𝜷
𝑇𝑿  
  
                   
aSymbol used in Holford and Buclin’s paper.1 
bSome of the concepts used by Diaz et al.2,3 are standard concepts from the statistical literature on random effects linear models. 
cSymbol(s) or formula used in Diaz et al.’s paper.2  
dDiaz et al.2,3 also computed an optimal target concentration, symbolized by 𝐶0
∗, when it is desired to reach a particular target concentration 
range. However, any desired target concentration can be input into their dose individualization algorithm, including the TC suggested in formula 
(1) of Holford and Buclin.1 
eThis is the variance of the random intercept,2 or in general, the compounded variances of the random effects in a more general formulation 
given in reference 3. 
fIn the general mathematical formulation given in reference 3, covariates that have random effects on plasma concentrations also contribute to 
the predictable variability. 
gSimilarly to the SEV concept of Holford and Buclin,1 the maximum attainable probability of a patient reaching the TCR (symbolized with 𝑚 by 
Diaz et al.2,3) is essentially a function of both the SECR and WSVU or, equivalently, of (𝑙1, 𝑙2) and 𝜎𝜖
2. Under a TCI, the exact relationship between 
𝜔 × 𝑚 and SEV is 𝜔 × 𝑚 = 1 − 2Φ(− (log √𝑙2 𝑙1⁄ ) SEV⁄ ), where Φ is the standard normal cumulative distribution function.  
hA limitation of Holford and Buclin1 paper is they do not specifically describe how to compute the ITD from a particular patient’s drug plasma  
concentration. However, they describe that the ITD is usually computed with a concentration produced in the patient by a group therapy dose 
(GTD). If an empirical Bayesian approach such as that proposed by Diaz et al.2,3 were used to carry out this computation, the ITD would 
correspond to 𝐷2, the dose computed at the second step of Diaz et al.’s individualization algorithm. Depending on the particular values of BSVU 
and WSVU, and of SECR, this dose may or may not be optimal according to the omega-optimality criterion of Diaz et al.2,3 If it is not optimal, 
additional algorithm steps are needed to obtain optimality. In general, depending on both how the ITD is computed and the patient population 
characteristics, the ITD may or may not be optimal in the sense that the probability that a particular patient reaches the SER with such dose may 
or may not be as high as possible. 
iDiaz et al.3,4 describe empirical and theoretical evidence from them and other authors demonstrating  that their statistical model is essentially a 
model of clearance when the log of steady-state drug plasma concentrations is used as the dependent variable and the drug follows linear 
pharmacokinetics.  
 
